Ampersand Capital Partners Majority Recapitalizes N2 Biomedical

Ampersand Capital Partners Majority Recapitalizes New England Peptide

October 7, 2019

Biotechnology

Ampersand Capital Partners completed a majority recapitalization of New England Peptide to support the company's worldwide growth initiatives and expand its peptide synthesis capabilities. As part of the transaction, Dr. José de Chastonay was appointed Executive Chairman; founders Sam and Jennifer Massoni remain noted in the announcement.

Ampersand Capital Partners Invests in Sterling Medical Devices

June 23, 2022

Medical Devices

Ampersand Capital Partners, a healthcare-focused private equity firm, made a growth equity investment in Sterling Medical Devices, a Moonachie, New Jersey-based provider of design, development and regulatory services for the medical device industry. The investment is intended to support Sterling’s continued growth and capability expansion across product development, software/electromechanical integration, and regulatory affairs.

Ampersand Capital Partners Majority Recapitalizes Phosphorex

August 25, 2022

Healthcare Services

Ampersand Capital Partners completed a majority recapitalization of Phosphorex to provide growth capital enabling the company to build out a 30,000 sq. ft. facility and establish cGMP manufacturing capabilities for lipid nanoparticles, microspheres and other drug-delivery platforms. The investment positions Phosphorex to expand from development and analytical services into end-to-end CDMO manufacturing to better serve pharmaceutical and biotechnology clients.

Ampersand Capital Partners Makes Growth Investment in Lexington Medical

April 17, 2025

Medical Devices

Ampersand Capital Partners has made a strategic growth investment in Lexington Medical, a Bedford, Massachusetts-based designer and manufacturer of minimally invasive surgical stapling devices. The investment will support Lexington's product innovation, smart manufacturing initiatives, and global market expansion while bolstering the company's US-based manufacturing and talent base.

Ampersand Capital Partners Invests in AnaBios Corporation

June 7, 2022

Healthcare Services

Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.

Ampersand Capital Partners Majority Recapitalizes Leinco Technologies

November 10, 2021

Biotechnology

Ampersand Capital Partners has completed a majority recapitalization of Leinco Technologies, a specialty manufacturer of life-science reagents and custom development services based near St. Louis, Missouri. The growth equity investment will fund expanded manufacturing capacity, broaden scientific capabilities and product offerings, and support Leinco's commercial and geographic expansion while leadership including founder Pat Leinert Sr. remain involved.